Arcus Biosciences (Arcus Biosciences) Price-to-Operating-Cash-Flow : (As of Apr. 28, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Arcus Biosciences Price-to-Operating-Cash-Flow?

As of today (2024-04-28), Arcus Biosciences's share price is $15.55. Arcus Biosciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.14. Hence, Arcus Biosciences's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Arcus Biosciences's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 8 years, Arcus Biosciences's highest Price-to-Operating-Cash-Flow Ratio was 75.19. The lowest was 2.66. And the median was 7.23.

RCUS's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.65
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Arcus Biosciences's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-1.17. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.14.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Arcus Biosciences was -168.00% per year.

During the past 8 years, Arcus Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was -40.70% per year. The lowest was -47.10% per year. And the median was -43.90% per year.

Arcus Biosciences Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Arcus Biosciences's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcus Biosciences Price-to-Operating-Cash-Flow Chart

Arcus Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

12.81

3.40

Arcus Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															3.40	-	-	-	-

Competitive Comparison of Arcus Biosciences's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Arcus Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcus Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's Price-to-Operating-Cash-Flow falls into.

Arcus Biosciences Price-to-Operating-Cash-Flow Calculation

Arcus Biosciences's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	15.55	/	-4.136
	=

Arcus Biosciences's Share Price of today is $15.55.
Arcus Biosciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.14.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Arcus Biosciences Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Arcus Biosciences's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcus Biosciences (Arcus Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcus Biosciences Inc (NYSE:RCUS) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

3928 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.arcusbio.com

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.

Executives

Goeltz Ii Robert C.	officer: Chief Financial Officer	343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Juan C. Jaen	director, 10 percent owner, officer: President	850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Jennifer Jarrett	officer: See Remarks	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Alexander Azoy	officer: Chief Accounting Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Terry J Rosen	director, 10 percent owner, officer: Chief Executive Officer	C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080
Carolyn C. Tang	officer: General Counsel	3928 POINT EDEN WAY, HAYWARD CA 94545
Dimitry Sa Nuyten	officer: Chief Medical Officer	740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710
Linda Slanec Higgins	director	3610 LOUIS RD., PALO ALTO CA 94303
Nicole Lambert	director	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
William Grossman	officer: Chief Medical Officer	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Yasunori Kaneko	director, 10 percent owner	509 ROEHAMPTON, HILLS BOROUGH CA 94010
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael Quigley	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew J Perlman	director	618 MIRADA AVE, STANFORD CA 94305